Butyl p-hydroxybenzoate


No ToxCast endpoints for intended target type: RNA

ToxCast endpoints for intended target type: Protein
Assay NameTissueOrganismTarget Gene IDTarget HGNC SymbolResponseAC50 Value
CCTE_Deisenroth_AIME_384WELL_LUC_InactiveMammary gland/breastHuman2099ESR1Gain4.27 μM
CCTE_Deisenroth_AIME_384WELL_LUC_ShiftMammary gland/breastHuman2099ESR1Inhibitory3.78 μM
CCTE_GLTED_hTTR_0.125uMHuman7276TTRLoss2.01 μM
CCTE_Deisenroth_DEVTOX-GLR_Endo_BRAPluripotent stem cellHuman6862TBXTGain135.96 μM
CCTE_Deisenroth_DEVTOX-GLR_Endo_SOX2Pluripotent stem cellHuman6657SOX2Gain
ATG_AP_2_CISLiverHuman7020|7021|83741TFAP2A|TFAP2B|TFAP2DActivatory135.57 μM
ATG_BRE_CISLiverHuman4086SMAD1Inhibitory125.58 μM
ATG_DR4_LXR_CISLiverHuman7376|10062NR1H2|NR1H3Activatory169.37 μM
ATG_ERE_CISLiverHuman2099ESR1Inhibitory3.39 μM
ATG_Ets_CISLiverHuman2113ETS1Inhibitory156.87 μM
ATG_GATA_CISLiverHuman2623GATA1Inhibitory163.86 μM
ATG_GLI_CISLiverHuman2735GLI1Activatory124.91 μM
ATG_HIF1a_CISLiverHuman3091HIF1AActivatory124.52 μM
ATG_HSE_CISLiverHuman3297HSF1Activatory147.64 μM
ATG_MRE_CISLiverHuman4520MTF1Activatory128.61 μM
ATG_Myb_CISLiverHuman4602MYBInhibitory161.86 μM
ATG_Oct_MLP_CISLiverHuman5451POU2F1Inhibitory116.48 μM
ATG_ERa_TRANSLiverHuman2099ESR1Gain2.3 μM
NVS_ADME_hCYP1A2Human1544CYP1A2Loss1.41 μM
NVS_ADME_hCYP2B6Human1555CYP2B6Loss4.55 μM
NVS_ADME_hCYP2C19Human1557CYP2C19Loss7.75 μM
NVS_ADME_hCYP2C9Human1559CYP2C9Loss5.38 μM
NVS_ADME_hCYP2D6Human1565CYP2D6Loss4.89 μM
NVS_NR_hERHuman2099ESR1Loss4.29 μM
NVS_NR_mERaMouse13982Esr1Loss7.31 μM
NVS_OR_gSIGMA_NonSelectiveBrainGuinea pig100135589Sigmar1Loss4.19 μM
BSK_3C_TissueFactorVascularHuman2152F3Inhibitory7.53 μM
ATG_BRE_CISLiverHuman4086SMAD1Activatory165.57 μM
ATG_ISRE_CISLiverHuman3659IRF1Inhibitory150.69 μM
ATG_MRE_CISLiverHuman4520MTF1Activatory142.74 μM
ATG_ERa_TRANSLiverHuman2099ESR1Gain2.37 μM
ATG_BRE_CISLiverHuman4086SMAD1Activatory171.39 μM
ATG_ERE_CISLiverHuman2099ESR1Inhibitory10.11 μM
ATG_ISRE_CISLiverHuman3659IRF1Activatory148.45 μM
ATG_BRE_CISLiverHuman4086SMAD1Inhibitory164.89 μM
ATG_E_Box_CISLiverHuman7391USF1Activatory137.68 μM
ATG_ERa_TRANSLiverHuman2099ESR1Gain5.74 μM
NVS_NR_hERHuman2099ESR1Loss8.78 μM
NVS_NR_mERaMouse13982Esr1Loss4.96 μM
NVS_MP_rPBRKidneyRat24230TspoLoss2.99 μM
NVS_NR_hERHuman2099ESR1Loss4.94 μM
NVS_MP_rPBRKidneyRat24230TspoLoss4.29 μM
NVS_NR_hERHuman2099ESR1Loss8.65 μM
NVS_NR_mERaMouse13982Esr1Loss5.53 μM
TOX21_p450_CYP1A2_AntagonistHuman1544CYP1A2Loss3.12 μM
TOX21_ERa_LUC_VM7_AgonistBreastHuman2099ESR1Gain4.19 μM
TOX21_p450_CYP1A2_AntagonistHuman1544CYP1A2Loss4.2 μM
TOX21_p450_CYP1A2_AntagonistHuman1544CYP1A2Loss5.58 μM

ToxCast endpoints for intended target type: Molecular messenger
Assay NameTissueOrganismTarget Gene IDTarget HGNC SymbolResponseAC50 Value
CEETOX_H295R_OHPROGAdrenal glandHuman5241PGRActivatory5.0 μM
CEETOX_H295R_PROGAdrenal glandHuman5241PGRInhibitory3.6 μM

ToxCast endpoints for intended target type: Pathway
Assay NameTissueOrganismTarget Gene IDTarget HGNC SymbolResponseAC50 Value
ACEA_ER_80hrBreastHuman2099ESR1Gain1.73 μM
ACEA_ER_80hrBreastHuman2099ESR1Gain1.78 μM
ACEA_ER_80hrBreastHuman2099ESR1Gain1.91 μM
OT_ER_ERaERb_0480KidneyHuman2099|2100ESR1|ESR2Gain5.16 μM
OT_ER_ERbERb_0480KidneyHuman2100ESR2Gain5.41 μM
OT_ER_ERbERb_1440KidneyHuman2100ESR2Gain6.38 μM
OT_ER_ERaERb_0480KidneyHuman2099|2100ESR1|ESR2Gain3.17 μM
OT_ER_ERbERb_0480KidneyHuman2100ESR2Gain5.25 μM
OT_ER_ERbERb_1440KidneyHuman2100ESR2Gain5.81 μM
OT_ER_ERaERb_0480KidneyHuman2099|2100ESR1|ESR2Gain4.44 μM
OT_ER_ERbERb_0480KidneyHuman2100ESR2Gain4.63 μM
OT_ER_ERbERb_1440KidneyHuman2100ESR2Gain4.49 μM

No ToxCast endpoints for intended target type: Cellular

No ToxCast endpoints for intended target type: Hormone

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.